Allergen-specific immunotherapy (ASIT) is the most effective method of treating allergic pathology. The method consists in the administration of small doses of the antigen, which was an etiological factor in the development of allergies, and in a particular patient. In this case, the body desensitizes to this antigen. The use of ASIT leads to a reduction in symptoms and the need for treatment and, in addition, has the potential for long-term clinical effect, preventing the development of allergies and its symptoms. Treatment acts on the main immunological mechanisms responsible for the development of clinical symptoms. ASIT is an anti–inflammatory, pathogenetic and preventive treatment of allergic respiratory tract diseases.

allergen-specific immunotherapy, sublingual immunotherapy, immunological mechanisms, subcutaneous immunotherapy, allergovaccines.

Antico A., Pagani M., Crema A. Anaphylaxis by latex sublingual immunotherapy. Allergy, 2006, Vol. 61, no. 10, pp. 1236-1237.

Arvidsson M.B., Lowhagen O., Rak S. Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy. J. Allergy Clin. Immunol., 2002, Vol. 109, no. 5, pp. 777-783.

Bae J.M., Choi Y.Y., Park C.O., Chung K.Y., Lee K.H. Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J. Allergy Clin. Immunol., 2013, Vol. 132, no. 1, pp. 110-117

Bagnasco M. Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j1) administered by noninjectable routes in healthy human beings. J. Allergy Clin. Immunol., 1997, Vol. 100, no. 1, pp. 122-129

Baldo B.A. Standardization of allergens. Examination of existing procedures and the likely impact of new techniques on the quality control of extracts. Allergy, 1983, Vol. 38, no. 8, pp. 535-546.

Bodtger U., Poulsen L.K., Jacobi H.H., Malling H.J. The safety and efficacy of subcutaneous birch pollen immunotherapy – a one-year, randomised, double-blind, placebo-controlled study. Allergy, 2002, Vol. 57, no. 4, pp. 297-305.

Bousquet J., Demoly P. Specific immunotherapy – an optimistic future. Allergy, 2006, Vol. 61, no. 10, pp. 1155-1158.

Bousquet J., Demoly P., Michel F.B. Specific immunotherapy in rhinitis and asthma. Ann. Allergy Asthma Immunol., 2001; Vol. 87, no. 1, Suppl. 1, pp. 38-42

Bousquet J., Lockey R., Malling H. WHO Position Paper. Allergen Immunotherapy: Therapeutic Vaccines for allergic diseases. Allergy, 1998, Vol. 53, Suppl. 54.

Bousquet J., Van Cauwenberge N. Khaltaev and the Workshop Expert Panel. Allergic Rhinitis and its Impact on Asthma (ARIA). Allergy, 2002, Vol. 57, no. 9, pp. 841-845.

Bozek A., Gawlik R., Jarzab J. (2014) The Prevention of New Sensitizations by Specific Immunotherapy: A Long-Term Observational Case Control Study. J. Allergy Ther., Vol. 5, p. 182.

Alimov Nurmukhammad, & Madumarova M.M. (2023). PHARMACOLOGICAL, FARMODYNAMIC PROPERTIES OF ANTIOXIDANT DRUGS. European International Journal of Multidisciplinary Research and Management Studies, 3(11), 17–20.